OrbiMed Advisors CYTK Position
Exited12-Fund ConvergenceOrbiMed Advisors exited their position in Cytokinetics Incorporated (CYTK) in Q3 2025, after holding the stock for 7 quarters.
The position was first reported in Q1 2024 and has been tracked across 7 quarterly 13F filings.
CYTK is a convergence signal: 12 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 16.4% of float with 8.6 days to cover, indicating significant bearish positioning against the stock.
About Cytokinetics Incorporated
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Full company profile →Short Interest
16.4%
8.6 days to cover
OrbiMed Advisors CYTK Position History
Frequently Asked Questions
Does OrbiMed Advisors own CYTK?
No. OrbiMed Advisors exited their position in Cytokinetics Incorporated (CYTK) in Q3 2025. They previously held the stock for 7 quarters.
How many hedge funds own CYTK?
12 specialist biotech hedge funds currently hold CYTK, including Deep Track Capital, RTW Investments, Boxer Capital and 9 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CYTK?
OrbiMed Advisors's position in CYTK was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CYTK position increasing or decreasing?
OrbiMed Advisors completely exited their CYTK position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CYTKCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →